Amplatzer Postmarket Study Should Address Age, Device Size Issues - Panel

FDA approval of AGA Medical's Amplatzer septal occluder should include a requirement for a five-year postmarket study of patients under 10 years of age who receive the device, the agency's Circulatory System Devices Panel recommended at its Sept. 10 meeting in Gaithersburg, Maryland.

More from Archive

More from Medtech Insight